LEADER 01749nam  2200349   450 
001 9910674022603321
005 20230624171220.0
035   $a(CKB)4920000000094741
035   $a(NjHacI)994920000000094741
035   $a(EXLCZ)994920000000094741
100   $a20230624d2018      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGlycosaminoglycans and Proteoglycans /$fBarbara Mulloy, editor
210  1$aBasel, Switzerland :$cMDPI,$d2018.
215   $a1 online resource (v, 215 pages) $cillustrations
311   $a3-03842-835-3 
320   $aIncludes bibliographical references.
330   $aProteoglycans (PGs) are glycoconjugates in which a protein or peptide core is substituted with polysaccharide chains known as glycosaminoglycans (GAGs). The GAG sidechains carry a significant proportion of the functionality of PGs, interacting with many proteins to form structural units in the extracellular matrix and to modulate the transport and signalling of small proteins acting as morphogens, growth factors and cytokines. Purified GAGs such as heparin and hyaluronan are in common use as therapeutic agents, with many more PG-based natural products, synthetic and semi-synthetic mimetics on the way; in addition, potential therapeutic strategies involving PG/GAG biosynthesis and degradation as targets are currently in development.
606   $aGlycosaminoglycans
615  0$aGlycosaminoglycans.
676   $a599.322
702   $aMulloy$b Barbara
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910674022603321
996   $aGlycosaminoglycans and Proteoglycans$92945089
997   $aUNINA